💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Prabotulinumtoxin A

CHEMBL4297229 Phase 4 Đã phê duyệt Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Prabotulinumtoxin A is a botulinum toxin type A product that acts by inhibiting the release of acetylcholine at the neuromuscular junction through cleavage of the SNAP-25 protein, causing temporary, localized muscle paralysis. It is approved for the treatment of chronic migraine prophylaxis and cosmetic treatment of glabellar lines.

Lĩnh vực điều trị

Neurology Migraine

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Prabotulinumtoxin A is a botulinum toxin type A product that acts by inhibiting the release of acetylcholine at the neuromuscular junction through cleavage of the SNAP-25 protein, causing temporary, localized muscle paralysis. It is approved for the treatment of chronic migraine prophylaxis and cosmetic treatment of glabellar lines.

Yes, Prabotulinumtoxin A is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297229. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.